Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC).

被引：7

作者：

Marteau, Florence ^{[1
]}

Harrow, Brooke ^{[2
]}

McCarthy, Christine ^{[3
]}

Wallace, Joel ^{[4
]}

Monnette, Alisha ^{[5
]}

Wang Yunfei ^{[6
]}

Doshi, Gurjyot K. ^{[7
]}

机构：

[1] IPSEN Pharma SAS, Boulogne, France

[2] Ipsen Inc, Cambridge, MA USA

[3] Ipsen, Boulogne, Ile De France, France

[4] Exelixis, Alameda, CA USA

[5] McKesson, The Woodlands, TX USA

[6] US Oncol Res, McKesson Specialty Hlth, The Woodlands, TX USA

[7] US Oncol Network, McKesson Specialty Hlth, Houston, TX USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.293

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

293

引用

页数：2